Kura Oncology, Inc. KURA
10.76
(0.10)
(0.92%)
as of 25 Sep
- Market cap
- $977.7M
- P/E
- 0.0×
Follow KURA
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(65.10%) | (94.82%) | (124.74%) | (167.71%) | |
| (38.45%) | (37.19%) | (42.19%) | (46.73%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(42.80%) | (46.48%) | (55.59%) | (66.12%) | |
Average Days of Receivables |
0.00 | 47.62 | 47.63 | 44.65 | |
Free Cash Flow per Share |
0.95 | (0.81) | (0.95) | (1.32) | |
Free Cash Flow |
83.11 | (70.70) | (84.46) | (117.43) | |
Capital Expenditures |
(4.69) | (6.64) | (6.47) | (5.67) | |
Piotroski F-Score |
3.00 | 4.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
10.95% | (7.53%) | (11.17%) | (19.36%) | |
Accounts Receivable Turnover |
0.00 | 12.42 | 2.47 | 11.02 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.03 | 0.03 | |
Inventory Turnover |
— | — | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 2,865.88 | 934.78 | |
Days of Inventory on Hand |
— | 0.00 | 343.03 | 971.12 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 372.06% | 363.44% | 335.99% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 177.80% | 179.65% | 175.18% | |
Share Based Compensation of Revenue |
0.00% | 54.99% | 52.60% | 50.43% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.40) | 0.23 | 0.26 | 0.38 | |
Depreciation/Fixed assets |
(1.24) | (0.95) | (0.73) | (0.48) | |
Capex/Depreciation |
0.51 | 0.89 | 1.16 | 1.55 | |
Revenue per Share |
0.00 | 0.77 | 0.81 | 0.87 | |
Operating CF per Share |
1.00 | (0.73) | (0.88) | (1.26) | |
Capex per Share |
(0.05) | (0.08) | (0.07) | (0.06) | |
Capex to Sales |
0.00 | 0.10 | 0.09 | 0.07 | |
Net Profit Margin |
0.00% | (412.95%) | (411.19%) | (384.30%) |
Columns are period end dates